62 / 69
62
reaction should not replace conventional cytogenetics for
monitoring patients with chronic myeloid leukemia
during early phase of imatinib therapy. Haematologica
2004;89:49-57.
58.
Lima L, Bernal-Mizrachi L, Saxe D, Mann KP, Tighiouart
M, Arellano M, et al. Peripheral blood monitoring of
chronic myeloid leukemia during treatment with imatinib,
second-line agents, and beyond. Cancer 2011;117:1245-52.
59.
Marin D, Kaeda J, Szydlo R, Saunders S, Fleming A,
Howard J, et al. Monitoring patients in complete
cytogenetic remission after treatment of CML in chronic
phase with imatinib: patterns of residual leukaemia and
prognostic factors for cytogenetic relapse. Leukemia
2005;19:507-12.
60.
Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P,
Holowiecki J, Jootar S, et al. Dasatinib or high-dose
imatinib for chronic-phase chronic myeloid leukemia after
failure of first-line imatinib: a randomized phase 2 trial.
Blood 2007;109:5143-50.
61.
Kantarjian H, Pasquini R, Lévy V, Jootar S, Holowiecki J,
Hamerschlak N, et al. Dasatinib or high-dose imatinib for
chronic-phase chronic myeloid leukemia resistant to
imatinib at a dose of 400 to 600 milligrams daily: two-year
follow-up of a randomized phase 2 study (START-R).
Cancer 2009;115:4136-47.
62.
Shah NP, Kantarjian HM, Kim DW, Réa D, Dorlhiac-Llacer
PE, Milone JH, et al. Intermittent target inhibition with
dasatinib 100 mg once daily preserves efficacy and
improves tolerability in imatinib-resistant and-intolerant
chronic-phase chronic myeloid leukemia. J Clin Oncol
2008;26:3204-12.
63.
Shah NP, Kim DW, Kantarjian H, Rousselot P, Llacer PE,
Enrico A, et al. Potent, transient inhibition of BCR-ABL
with dasatinib 100 mg daily achieves rapid and durable